(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 6 March 2008 (06.03.2008)

(51) International Patent Classification:

A61K 47/10 (2006.01) A61K 31/5513 (2006.01) A61K 47/14 (2006.01) A61P 25/08 (2006.01)

A61K 47/22 (2006.01)

(21) International Application Number:

PCT/US2007/018942

(22) International Filing Date: 27 August 2007 (27.08.2007)

(25) Filing Language: **English**

(26) Publication Language: English

(30) Priority Data:

60/840,568 28 August 2006 (28.08.2006) US

(71) Applicant (for all designated States except US): JAZZ PHARMACEUTICALS [US/US]; 3180 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): JAMIESON, Gene [US/US]; 18155 China Grade, Boulder Creek, CA 95006 (US). DES JARDIN, Michael [US/US]: 670 Lamberth Court, Sunnyvale, CA 94087 (US). ALLPHIN, Clark [US/US]; 150 Giffin Road, Apartment 4, Los Altos, CA 94022 (US).
- (74) Agent: CAGAN, Felissa, H.; Jazz Pharmaceuticals, 3180 Porter Drive, Palo Alto, CA 94304 (US).

(10) International Publication Number WO 2008/027395 A3

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 17 April 2008



(54) Title: PHARMACEUTICAL COMPOSITIONS OF BENZODIAZEPINES AND METHODS OF USE THEREOF

(57) Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.

International application No

PCT/US2007/018942 A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K47/10 A61K47/14 A61K31/5513 A61P25/08 A61K47/22 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, EMBASE, BIOSIS, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Refevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages FR 2 656 303 A (PARKE DAVIS [FR]) 1-19,21,X 28 June 1991 (1991-06-28) page 1, lines 5-10 page 2, lines 16-32 page 3, line 25 - page 4, line 3 claims 1-6 WO 2004/004783 A (FOSCAMA BIOMED CHIM X 1-13, FARMA [IT]) 15 January 2004 (2004-01-15) 15-19. 21,24 page 1, lines 6-25 page 8, lines 16-25 page 9, line 32 - page 11, line 6 page 14, line 14 - page 15, line 4 page 18, lines 5-14 claims 1-6,11,12-/--Further documents are listed in the continuation of Box C. X See patent family annex. Special categories of cited documents: *T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "O" document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but "&" document member of the same patent family later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report 25/02/2008

Name and mailing address of the ISA/

13 February 2008

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Authorized officer

GOMEZ GALLARDO, S

C(Continue	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	FC1/03200//018942
Category.*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 693 608 A (BECHGAARD ERIK [DK] ET AL) 2 December 1997 (1997-12-02) column 3, line 43 - column 4, line 22 column 5, lines 32-41 column 6, lines 14-41 column 6, line 66 - column 7, line 4 column 7, line 9 - column 8, line 46 column 9, lines 17-26 column 15 - column 16; examples 2,3 column 16 - column 19; examples 6-8,11 column 27 - column 30; tables 1-4 column 31, lines 45-64 & WO 91/16929 A (NOVONORDISK AS [DK]) 14 November 1991 (1991-11-14) cited in the application	1-24
X	US 2006/153905 A1 (CARRARA R D N [CH] ET AL) 13 July 2006 (2006-07-13) page 1, paragraph 2 page 4, paragraphs 31-34,49 page 5, paragraphs 59,65 page 6, paragraphs 69,70 page 6, paragraph 73 - page 7, paragraph 73 page 8, paragraph 81 page 11; examples 28-30	1-24
X	WO 02/11768 A (ANTARES PHARMA IPL AG [CH]) 14 February 2002 (2002-02-14) page 9, lines 4-16 page 10, lines 9,10 page 21 - page 23; examples 23-28,30	1-24
X	WO 01/06987 A (SK CORP [US]) 1 February 2001 (2001-02-01) page 5, lines 6-29 page 8 - page 16; examples 3-9	1,4-9, 12-24
X	& US 6 627 211 B1 (CHOI YONG MOON [US] ET AL) 30 September 2003 (2003-09-30) cited in the application	1,4-9, 12-24
X	HOU H, SIEGEL R A: "Enhanced permeation of diazepam through artificial membranes from supersaturated solutions" JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 95, no. 4, 2006, pages 896-905, XP002468332 cited in the application abstract page 898, left-hand column, last paragraph page 898, right-hand column, paragraph 2 page 899, right-hand column, paragraph 2 page 902, left-hand column, paragraph 3	1-9, 12-14, 16-24
	_/	

C(Continua	ition). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PUGLIA C ET AL: "Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations" INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 228, no. 1-2, 2001, pages 79-87, XP002467561 abstract page 80, right-hand column, last paragraph - page 81, left-hand column, paragraph 1 page 81; table 1	1-11,13, 15-19,21
X	CRANKSHAW D P ET AL: "THE EFFECT OF SOLVENTS ON THE POTENCY OF CHLORDIAZEPOXIDE, DIAZEPAM, MEDAZEPAM AND NITRAZEPAM" JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, GB, vol. 23, no. 5, 1971, pages 313-321, XP008088376 ISSN: 0022-3573 abstract page 314, paragraph 1-3	1-9,13, 14, 16-19, 21,24
X	WO 2004/110403 A (SK CORP [KR]) 23 December 2004 (2004-12-23) cited in the application page 1, paragraph 1 page 3, paragraph 8 page 4; table 1 page 4, paragraph 16 - page 5, paragraph 16	1,4 - 9, 12-14, 16-24
X	US 2005/163719 A1 (DUGGER HARRY A III [US] ET AL) 28 July 2005 (2005-07-28) page 1, paragraph 11 page 3, paragraph 34 page 5, paragraph 69 page 12; example 13	1,4-9, 12-14, 16-19, 21,24
X	WO 2006/075123 A (CAMURUS AB [SE]) 20 July 2006 (2006-07-20) page 44; example 25 -/	1,4-9, 12-14, 16-24

Ciccontrovation) DOCUMENTS CONSIDERED TO BE RELEVANT Category' Citation of document, with indication, where appropriate, of the relevant passages P, X MO 2006/122217 A (UNIV MINNESOTA [US]) 16 November 2006 (2006–11-16) page 1, paragraph 2 page 6, paragraph 14,15 page 7, paragraph 16 page 11, paragraph 26 page 11, paragraph 56 – page 12, paragraph 59 page 28, paragraph 171–174 claims 1–57
P,X WO 2006/122217 A (UNIV MINNESOTA [US]) 16 November 2006 (2006-11-16) page 1, paragraph 2 page 6, paragraphs 14,15 page 7, paragraph 19 page 8, paragraph 26 page 11, paragraph 56 - page 12, paragraph 59 page 28, paragraph 171-174
16 November 2006 (2006-11-16) page 1, paragraph 2 page 6, paragraphs 14,15 page 7, paragraph 19 page 8, paragraph 26 page 11, paragraph 56 - page 12, paragraph 59 page 28, paragraph 171-174
1

International application No. PCT/US2007/018942

INTERNATIONAL SEARCH REPORT

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This internati	onal search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
bec	ms Nos.: ause they relate to subject matter not required to be searched by this Authority, namely: though claims 22 and 23 are directed to a method of treatment of the
hu	man/animal body, the search has been carried out and based on the alleged fects of the composition.
bec	ms Nos.: ause they relate to parts of the international application that do not comply with the prescribed requirements to such extent that no meaningful international search can be carried out, specifically:
3. Clai	ms Nos.: ause they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of Invention is lacking (Continuation of item 3 of first sheet)
This Internati	onal Searching Authority found multiple inventions in this international application, as follows:
1. As a	all required additional search fees were timely paid by the applicant, this international search report covers allsearchable ns.
	all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of tional fees.
	only some of the required additional search fees were timely paid by the applicant, this international search reportcovers those claims for which fees were paid, specifically claims Nos.:
4. No rest	required additional search fees were timely paid by the applicant. Consequently, this international search report is ricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on l	The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest
	fee was not paid within the time limit specified in the invitation.
	No protest accompanied the payment of additional search fees.

Information on patent family members

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
FR 2656303	Α	28-06-1991	NONE			
WO 2004004783	Α	15-01-2004	AU IT	2003281197 RM20020357		23-01-2004 05-01-2004
US 5693608	Α	02-12-1997	NONE			
WO 9116929	Α	14-11-1991	AT	164080		15-04-1998
			AU	687496		26-02-1998
			AU	1358695		01-06-1995
			AU	654950		01-12-1994
			AU	7643591 7880991		14-11-1991 27-11-1991
			AU CN	1056812		11-12-1991
			CS	9101361		15-04-1992
4			DE	69129110		23-04-1998
		•	DE		T2	10-12-1998
			DK		T3	28-12-1998
			ĒΡ	0532546		24-03-1993
			ES	2117642		16-08-1998
			ΙE	911577		20-11-1991
			JP	3219096		15-10-2001
			JP	5507085		14-10-1993
			PT	97610	Α	31-01-1992
US 2006153905	A1	13-07-2006	NONE			
WO 0211768	A	14-02-2002	AR	030312	A1	20-08-2003
			ΑT	355854	Τ	15-03-2007
			ΑT	356636	T	15-04-2007
			AU	8206401		18-02-2002
			CA	2418135		14-02-2002
			DE	60127134		08-11-2007
			DE	60127277		29-11-2007
			ES ES	2283425		01-11-2007 01-11-2007
			JP	2283665 2004505931		26-02-2004
			NZ	524423		30-04-2004
			US	2003199426		23-10-2003
WO 0106987	Α	01-02-2001	AR	031072		10-09-2003
			AU	778896		23-12-2004
			AU	6118500		13-02-2001
			CA	2379365		01-02-2001
			CN Ep	1364079 1196156		14-08-2002 17-04-2002
			JP	2003505403		17-04-2002
			MX	PA02001612		14-10-2003
			TW	269652		01-01-2007
US 6627211	B1 	30-09 - 2003	US	2004028617		12-02-2004
WO 2004110403	Α	23-12-2004	AU	2004246961		23-12-2004
			BR	PI0411572		08-08-2006
			CA	2529489		23-12-2004
			CN	1826097		30-08-2006
			EP JP	1633326 2006527764		15-03-2006 07-12-2006
				700007//04	1	0/-12-2000

Information on patent family members

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004110403	1	KR 20060012030 A MX PA05014060 A	06-02-2006 17-03-2006
US 2005163719	1 28-07-2005	US 2004265239 A1 US 2004141923 A1 US 2004120895 A1 US 2005002867 A1	30-12-2004 22-07-2004 24-06-2004 06-01-2005
WO 2006075123	20-07-2006	CA 2594710 A1 CA 2594718 A1 EP 1848403 A1 EP 1845942 A1 WO 2006075125 A1	20-07-2006 20-07-2006 31-10-2007 24-10-2007 20-07-2006
WO 2006122217	16-11-2006	US 2007021411 A1 US 2007208011 A1	25-01-2007 06-09-2007